patients are of questionable value for risk stratification, most probably due to unspecific elevations. Background. Moderate elevations of cardiac troponin ( Tn) T, up to levels presumably diagnostic for minor
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laboratory. For cardiac troponin I and T determination, 5 ml Patients with renal disease, and especially those lithium-heparin blood was centrifuged at 5°C (10 min, 3000 undergoing haemodialysis therapy, are likely to have r.p.m.). Three aliquots of at least 500 ml were immediately coronary artery disease [22] . Since patients with frozen at −80°C. The dialysis regimen was at the discretion chronic renal failure frequently have elevated CK or of the physician in charge, who was not involved in the study. myoglobin levels [23] , measurement of cardiac troponins may be advantageous. Clinical observations suggest Analytical methods that troponin T yields false-positive values for the diagnosis of acute coronary syndromes [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] but Plasma concentrations of sodium, potassium, and creatinine less false-positive troponin I values [12, [28] [29] [30] [31] 33, 34] were measured with a DAXA 72 clinical chemistry analyser were observed in patients with end-stage renal disease (Bayer) using routine procedures. CK, CKMB, and myoglo-( ESRD) undergoing haemodialysis therapy (HD) or bin were measured with a Hitachi 911A system using system test kits (Roche Diagnostics). The CK activity was deterin pre-ESRD patients. Most of these references are mined according to the standard procedures of the German merely case reports and not controlled studies and do Society for Clinical Chemistry with upper reference limits up not indicate crucial aspects such as patient characterto 70 U/l for females and 80 U/l for males. Normal levels istics, how acute coronary syndromes were excluded, for CKMB, determined kinetically after immunoinhibition, and the threshold for the troponin values. It remains are up to 10 U/l or less than 0.06 of total CK activity. uncertain whether the false-positive diagnosis of min-Myoglobin was measured by a latex amplified immunoturbidimal myocardial damage is due to the threshold values imetric test with a reference range up to 70 mg/l. The biochemchosen and whether cardiac troponins are of prognostic ical criteria for acute myocardial infarction (AMI ) are 100 value in renal patients. The aim of the present study U/l CK with more than 0.06 of CKMB and 90 mg/l was to evaluate whether there are elevations in cardiac myoglobin.
Cardiac troponins were measured from frozen samples troponin T and troponin I (measured by two different (see above) which were rapidly thawed at 21°C, centrifuged tests) in patients with renal disease without evidence for 5 min at 2500 r.p.m. and immediately processed with the of an acute coronary syndrome (ACS ) using the latest 3 different troponin assays.
generation immunotests. Subgroup analysis of creatinine clearance correlation with troponin values in Cardiac troponin T patients with chronic renal failure before dialysis and the influence of the dialysis modality was performed. This was measured with an Elecsys 2010A analyser using a A 9-month follow up for acute myocardial infarction, newly developed immunoassay employing two monoclonal re-hospitalization and death addressed the question murine antibodies specific for cardiac troponin T and electrowhether troponin elevations are of diagnostic/pro-chemiluminescence as the detection technique (Roche gnostic value.
Diagnostics; 4). The sensitivity was 0.01 mg/l, the detection range was 0.01-25.0 mg/l and the interassay CV was 0.093 at low level concentrations (mean 0.1 mg/l ), 0.061 at inter-
Subjects and methods
mediate levels (mean 0.33 mg/l ) and 0.045 at high levels (mean 5.9 mg/l ). The analytical procedure is completed Patients within 9 min.
Cardiac troponin I was measured by means of two different We included 40 consecutive hospitalized patients with plasma commercially available tests: DADE (TnID), and Behring creatinine elevations above 1.5 mg/dl (pre-end-stage renal Diagnostics (TnIB). disease, pre-ESRD; n=20) or who were on chronic haemoThe immunofluorescence assay, Stratus IIA, employing a dialysis therapy for at least 1 month (ESRD; n=20). monoclonal capture antibody and a alkaline phosphataseExclusion criteria were: haemoglobin below 8.0 g/dl, age labelled secondary antibody was used for TnID determinaabove 80 years or severely compromised clinical status, tion. The analytical sensitivity was 0.35 mg/l, the measuring known neoplastic disease, acute renal failure, any angina range was 0.35-50 mg/l and the interassay CV was 0.085 at pectoris symptoms occuring during the last 14 days or an low level concentrations (mean 5.1 mg/l ), 0.075 at interacute coronary syndrome (unstable angina, acute myocardial mediate levels (mean 18.5 mg/l ) and 0.044 at high levels infarction; ACS ) in the last 4 weeks. All patients gave (mean 33.4 mg/l ). The analytical procedure is completed informed consent. Table 1 shows the clinical characteristics within 10 min. of the patients and the renal and concomitant diseases are
The immunofluorescence assay, Behring OPUS PlusA, listed in Table 2 . The mode of haemodialysis, especially the containing two polyclonal goat antibodies against cardiac type of membrane used was left to the discretion of the troponin I and was used to measure TnIB. The analytical attending physician. The membranes used were recorded and sensitivity was 0.5 mg/l, the measuring range was listed below. 0.5-150 mg/l, and the interassay CV was 0.045 at low level concentrations (mean 3.7 mg/l ), 0.056 at intermediate levels (mean 19.5 mg/l ) and 0.0477 at high levels (mean 99.1 mg/l ).
Protocol
The analytical procedure is completed within 20 min. Cardiac history, 12-lead ECG and echocardiography were performed in all patients to determine the cardiac status. Threshold values Blood samples were taken immediately before and after haemodialysis, and in pre-ESRD patients once at 8.00 a.m. The selection of cut-off values is essential for the comparison Plasma concentrations of sodium, potassium, creatinine, of different analytical methods. As described above, the creatine-kinase and its isoenzyme MB (CKMB), and myoglo-characteristics of the three tests differ widely. First, the range of troponin T is different from that of TnI due to assay bin were measured within 2 h in our central clinical chemistry callibration issues. Second, the plasma of healthy blood frequencies were too small for Chi-square testing. The distribution of quantitative variables were not normally distribdonors does usually not contain measurable concentrations of TnT. Third, the two different TnI tests are not standard-uted, and therefore non-parametric tests were chosen. The values are listed as medians and range. ized. Thus, the analytical results do not represent the same amount of substance and it is not possible to calculate a To determine whether troponin values independently predict outcome, a logistic regression was performed including fixed relation between the test results.
Three different threshold values for the troponin markers the variables age, sex, group (ESRD or pre-ESRD) and troponin. The sample size was estimated using MedCalcA were used as described in the literature and as outlined by the manufacturers of the assays. The cut-off values indicating statistical software (alpha-error 0.05, beta-error 0.2) on the basis of event rates for troponin T positive and negative minor myocardial damage (MMD) and increased risk of future cardiac events were 0.1 mg/l for TnT [17] [18] [19] , 0.4 mg/l patients reported in the literature. Event rates lay between 0.059 and 0.204 for troponin T positive and between 0.016 for TnID [20] and 2.0 mg/l [21,35] and 1.6 mg/l [36 ] for TnIB. The threshold for acute myocardial infarction (AMI ) and 0.087 for troponin T negative patients [37, 38] , depending on the population selected. The calculations resulted in was 0.5 mg/l for TnT [11] , 3.1 mg/l for TnID [12] and 2.5 mg/l for TnIB [13] . The generally suggested cut-off values for sample sizes of 31-47 patients. Therefore, we decided to include at least 40 patients. Further calculations and graphics myocardial injury (including both AMI and MMD) which could be obtained by the companies at the time of analytical were performed on a personal computer using SPSSA Inc. statistical software. testing were 0.1 mg/l for TnT, 1.5 mg/l for TnID, and 2.0 mg/l for TnIB. Unpublished data from patients with suspected AMI (A. Wu, personal communication) suggest an infarction cut-off of 0.2 mg/l for TnT which was additionally included in the analysis.
Results

Follow up
The levels of cardiac markers are listed in Table 3 . The type of dialyser membrane did not influence the cardiac The composite primary end-point: acute myocardial infarc-markers which were not different before and after tion, death from all causes, and re-hospitalization was dialysis therapy or between the ESRD/pre-ESRD recorded for all patients. The median follow up time was 9 groups. Low-flux membranes were used in 11 patients (7) (8) (9) (10) (11) and specificity for acute myocardial infarction. All [range] three cardiac markers are elevated beyond the minor 9-month follow-up was completed in ESRD and pre-ESRD patients for the first time. We could not show
Values are decimal fractions and 0.95 confidence intervals; #, onethat these markers have a significant prediction sided, 0.975 confidence interval; ESRD, end-stage renal disease; of mortality, acute myocardial infarction, or re-CAD, coronary artery disease; MI, myocardial infarction; HLP, hospitalization. Although the number of patients hyperlipoproteinemia (serum cholesterol>200 mg/dl ); HFBG, high evaluated is higher than in previous studies, the number fibrinogen (>300 mg/dL); HU; high uric acid (>10 mg/dL); GN, glomerulonephritis; PKD, polycystic kidney disease. is still relatively low for outcome analysis. Table 5 contains the cardiac troponin levels of seven patients who died or suffered from acute myocardial infarction T values are plotted against TnID ( Figure 1 ) and TnIB (Figure 2) . in the follow-up. As shown in Figures 1, 2 and Table 5 , the different troponins do not correlate and no test is Table 5 shows the troponin values of seven patients (0.18) who died or experienced acute myocardial clearly superior. This may be due to the fact that troponins are released as T-I-C complex, followed by infarction during the follow up period. Twenty-two patients (0.55) were re-hospitalized; five (0.13) for degradation in the circulation. The different test systems have various affinities for the T-I-C, I-C complex cardiac causes (acute myocardial infarction, pulmonary oedema, hypotension, pleural effusion). Using the or free troponin T [40] . Some events were correctly predicted by troponin elevations and possibly larger different cut-off values defined above, the logistic regression showed no significant prediction of the trials would be able to show significance.
Although more patients have to be observed for a primary endpoint by troponin values. The lowest applicable cut-offs odds ratios (0.95 CI ) were: 4.57 longer period to gain more evidence regarding the dialysis patients in their study, 0.17 had elevations prognostic implications of troponins in renal disease, the explanation of our findings could be a molecular using a second-generation TnT assay [4] , but only 0.04 in the TnID test. The cut-off in the McLaurin study change in muscle properties in uraemia. No cardiac troponin I isoform (fetal or adult) has been reported was defined as 0.8 mg/l. This is not appropriate, because a 0.4 mg/l cut-off value of TnID was shown to be of for skeletal muscle, but several reports exist for troponin T. Bodor et al. [41] described cardiac troponin prognostic value in the study by Antman and colleagues [20] . The second major concern regarding the T expression in regenerating (polymyositis, Duchenne muscular dystrophy) and normal skeletal muscle. study by McLaurin et al. [33] is that four of the five patients had serum TnT values below the detection Unfortunately the antibody used by Bodor and colleagues was different from the monoclonal antibodies limit. The fifth patient had a serum concentration of 0.1 mg/l, which is exactly the threshold value for minor in the improved second-generation test used in our study. These antibodies have been shown to be nearly myocardial damage. Therefore, skeletal muscle expression of cardiac TnT is not shown to be the cause of 100% cardiospecific in Western blot analysis by the company. McLaurin et al. [33] have shown that cardiac plasma troponin T elevations in asymptomatic HD patients. This is supported by new work of Ricchiutti troponin T, but not troponin I was expressed in skeletal muscle biopsies in four of five dialysis patients. Of 24 et al. [42] , who showed that the second-generation troponin T assay does not detect fetal and regenerative difference was only significant for TnID with its lowest cut-off ), mortality was higher in the pre-ESRD group. troponin T. Another important issue is addressed by work of Anderson et al. [43] who show that the failing This may be due to a selection bias because the age was higher and the degree of illness seemed to be more human heart expresses more of the troponin T isoform 2 compared to normal cardiac tissue. Again in this severe in the pre-ESRD group ( Table 1) .
Although we could show that several patients with study, no cardiac troponin T was found to be expressed in skeletal muscle specimens [43] . Therefore, it is renal failure have non-diagnostic elevations of troponin, determination of cardiac troponins is of possible unlikely that detection of troponins in asymptomatic uraemic patients is due to molecular changes in skeletal benefit in patients with acute coronary syndromes. to incomplete diagnostic studies in several of the 56 As it is known from other biochemical analyses (e.g. patients. Larger studies including consecutive uraemic parathyroid hormone), especially in HD patients, the patients, with and without angina pectoris symptoms, metabolism of troponins may be altered, and detection have to be performed to evaluate cardiac troponin use of troponin degradation products may lead to analyt-in renal disease patients. ical results judged to be false positive [44] . However, troponin degradation products have not been described
Conclusions
in the literature up to now. Additionally, binding sites of test antibodies could be altered due to changes in
In uraemic patients without signs of acute cardiac protein kinase C (PKC ) properties in renal patients as disease, cardiac troponin I and T are frequently elev-PKC phosphorylates troponin T and I at many differated above threshold values which are usually diaent sites [45] .
gnostic for minor myocardial damage. Moderate Another explanation for higher troponin levels in troponin elevations do not predict outcome in these uraemic patients may be asymptomatic chronic patients. It is concluded that increased troponins in uraemic myopathy with continuous release of troponasymptomatic renal patients are of questionable value ins. This explanation is speculative and no clinical or for risk stratification most probably due to unspecific experimental data are available at present to support elevations. this hypothesis.
We have shown that TnT and TnI may be asympto-when a 0.4 mg/l cut-off was used. 
